Nuclera announces expansion with new US subsidiary

CAMBRIDGE, UK (18 Jan 2022) – Nuclera, a Cambridge, UK-based biotech company developing cutting-edge benchtop protein printing technologies, announces the opening of its US subsidiary located in Boston, MA.

The addition of this new US facility in the rapidly growing biotechnology hub of greater Boston USA is a critical step in the company’s plans and will pave the way for the delivery of Nuclera’s revolutionary eProtein™ desktop bioprinter, offering unprecedented speed and convenience for biotherapeutics, agribiotech and other markets of global importance. Nuclera’s eProtein™ bioprinter is born out of a strategic partnership with E Ink, the pioneers of ePaper, allowing the combination of biopolymer synthesis technologies with digital microfluidics.

The new US facilities are the result of a $4.5 million E Ink renovation, reinforcing Nuclera’s position as a technological innovator in the bioprinting space. “Our new laboratories and pilot manufacturing facilities in Boston will support Nuclera’s goal to commercialize its eProtein™ technology significantly accelerating drug discovery workflows”, says Dr Michael Chen, CEO and cofounder of Nuclera.

Read More